PCM
REGN icon

Pentwater Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pentwater Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,000
Closed -$1.83M – 121
2016
Q4 		$1.83M Buy
+5,000
New +$1.9M 0.02% 100

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Pentwater Capital Management's REGN Position: Q3 2021 in Review

Pentwater Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 6,500 shares — an estimated $3.63M sold.

Pentwater Capital Management first reported a position in REGN in Q2 2020 and held it in 5 quarters. The position peaked at $4.05M in Q2 2020. 1,018 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • Pentwater Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Pentwater Capital Management sold 6,500 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $3.63M.
  • Pentwater Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • Pentwater Capital Management's Regeneron Pharmaceuticals position peaked at $4.05M in Q2 2020.
  • 1,018 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Pentwater Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.